Literature DB >> 8383220

Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

M Hijikata1, Y K Shimizu, H Kato, A Iwamoto, J W Shih, H J Alter, R H Purcell, H Yoshikura.   

Abstract

The buoyant density of hepatitis C virus (HCV), with high in vivo infectivity (strain H) or low in vivo infectivity (strain F), was determined by sucrose gradient equilibrium centrifugation. Viral RNA of strain H was detected in fractions with densities of < or = 1.09 g/ml (principally approximately 1.06 g/ml), while that of strain F was found in fractions with densities of approximately 1.06 and approximately 1.17 g/ml. The observed difference was confirmed by differential flotation centrifugation; in NaCl solution with a density of 1.063 g/ml, most of the HCV RNA of strain H was detected in the top fraction, while that of strain F appeared in the bottom. The same relationship between buoyant density and infectivity was observed in flotation centrifugation experiments with other HCV strains. In immunoprecipitation experiments with anti-human immunoglobulin, HCV (as measured by HCV RNA) was precipitated from the samples with low infectivity and high density but not from those with high infectivity and low density. Examination of serial sera from a chimpanzee infected with HCV revealed parallel changes in the buoyant density and immunoprecipitability of HCV-associated RNA during the course of infection. These data suggest that HCV is bound to anti-HCV antibodies as antigen-antibody complexes in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383220      PMCID: PMC240263     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Early events in hepatitis C virus infection of chimpanzees.

Authors:  Y K Shimizu; A J Weiner; J Rosenblatt; D C Wong; M Shapiro; T Popkin; M Houghton; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Characterization of N-type and dually permissive cells segregated from mouse fibroblasts whose Fv-1 phenotype could be modified by another independently segregating gene(s).

Authors:  H Yoshikura; S Tejima; T Kuchino; K Segawa; T Odaka
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

4.  Hepatitis B core antigen. Detection of antibody by radioimmunoprecipitation.

Authors:  Y Moritsugu; J W Gold; J Wagner; R Y Dodd; R H Purcell
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

5.  Determining the size of non-A, non-B hepatitis virus by filtration.

Authors:  L F He; D Alling; T Popkin; M Shapiro; H J Alter; R H Purcell
Journal:  J Infect Dis       Date:  1987-10       Impact factor: 5.226

6.  Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups.

Authors:  R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

7.  Non-A, non-B hepatitis in chimpanzees and marmosets.

Authors:  S M Feinstone; H J Alter; H P Dienes; Y Shimizu; H Popper; D Blackmore; D Sly; W T London; R H Purcell
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

8.  Transmissible agent in non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; P V Holland; H Popper
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

9.  Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform.

Authors:  S M Feinstone; K B Mihalik; T Kamimura; H J Alter; W T London; R H Purcell
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

10.  Detection of hepatitis C viral sequences in non-A, non-B hepatitis.

Authors:  A J Weiner; G Kuo; D W Bradley; F Bonino; G Saracco; C Lee; J Rosenblatt; Q L Choo; M Houghton
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  90 in total

1.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Immune complex of hepatitis C virus particles detected by immunogold electron microscopy.

Authors:  Masahiko Kaito; Esteban C Gabazza; Naoki Fujita; Hideaki Tanaka; Shozo Watanabe; Michinori Kohara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

Review 3.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

4.  The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection.

Authors:  Jian Tao; Kyung-Don Kang; Stacy D Hall; Audra H Laube; Jia Liu; Matthew B Renfrow; Jan Novak; Guangxiang Luo
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

5.  Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases.

Authors:  J Miyaike; Y Iwasaki; A Takahashi; H Shimomura; H Taniguchi; N Koide; K Matsuura; T Ogura; K Tobe; T Tsuji
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  The association of complement activation at a low temperature with hepatitis C virus infection in comparison with cryoglobulin.

Authors:  K Ueda; H Nakajima; T Nakagawa; A Shimizu
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons.

Authors:  Y K Shimizu; H Yoshikura
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Authors:  Kazi Abdus Salam; Richard Y Wang; Teresa Grandinetti; Valeria De Giorgi; Harvey J Alter; Robert D Allison
Journal:  Hepatology       Date:  2018-11-01       Impact factor: 17.425

9.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.